**Guideline Page and Request**

**Gastrointestinal Stromal Tumors (GISTs)**

**GIST-6**

**Internal request:**
For patients who have undergone complete resection and did not receive preoperative imatinib, consider changing the recommendation for the use of postoperative imatinib for patients with significant risk of recurrence (intermediate or high risk) from category 2A to category 1 based on Phase III data.

**Panel Discussion:**
Based upon discussion and phase III data, for patients who have undergone complete resection and did not receive preoperative imatinib, the panel consensus was to change the recommendation for the use of postoperative imatinib for patients with significant risk of recurrence (intermediate or high risk) from category 2A to category 1.

**References:**

**Vote**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>